Targovax: CFO turned CEO
Norwegion immuno-oncology play Targovax has promoted Øystein Soug, previously the companys Chief Financial Officer, to the role of Chief Executive Officer. He succeeds Gunnar Gårdemyr, who has stepped down.
Soug joined Targovax in 2015. Previously, he held the position of CFO at Norwegian oncology biotech Algeta. Prior to joining Algeta in 2008, Soug worked for Orkla, lastly as CFO of Orklas Russian division.
Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. He received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997
Targovax is now looking for a new CFO.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium